ClinicalTrials.gg
RecruitingNCT06741241Updated Oct 14, 2026

Effectiveness of an eHealth Intervention for Uptake of Cervical Cancer Screening in Hispanic Women

An interventional study of eHealth Promotora and eHealth Healthy Nutrition in Cervical Cancer Screening, sponsored by Florida A&M University. Recruiting at 1 site in United States. Open to female participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Florida A&M University · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 14, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Planned enrollment
213th of 678
170 · median 71
Started
2026
with 29 others
No phase
246 of 834
51 open now
Primary completion
2029-03
later than 183 of 217 live
Registered
766th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 213th largest by planned enrollment of the 678 interventional ones that give a count, is one of 30 that started in 2026, is one of 246 with no phase, reaches primary completion later than 183 of the 217 other live ones, and was the 766th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 143 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 21 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will test the effectiveness of an eHealth promotora (lay health advisor) outreach strategy to increase cervical cancer screening in Hispanic women. The investigators will recruit 160 Hispanic women ages 21-65 who are not up to date with cervical cancer screening or have never been screened, with the goal to evaluate screening knowledge, behavior, and intervention effects on cervical cancer screening outcomes. The study will utilize a two-arm, cluster randomized trial design, and participants will be randomly assigned to the cervical cancer education intervention or a nutrition education control group. The cervical cancer education arm will utilize a promotora to deliver an educational session virtually to encourage cervical cancer screening and receive a resource list for screening sites. The control group will participate in an educational session virtually about the importance of healthy nutrition. The primary study outcome is receipt of cervical cancer screening measured six months following receiving the intervention. The secondary outcomes will include cervical cancer screening knowledge and self-efficacy (confidence to receive cervical cancer screening). The research objective is to test the eHealth promotora intervention effectiveness for promoting cervical cancer screening in an under-screened Hispanic population.

03

Conditions studied

  • Cervical Cancer Screening
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. between the age of 21 and 65 years
  2. identify as Hispanic
  3. not up-to-date with cervical cancer screening [never screened or last Pap test ≥ 3 years - based on U.S. Preventive Services Task Force guidelines]
  4. have no history of cervical cancer
  5. have not had a hysterectomy.

Exclusion criteria

Exclusion Criteria:

  1. under the age of 21 or over the age of 65 years
  2. do not identify as Hispanic
  3. up-to-date with cervical cancer screening [last Pap test \< 3 years - based on U.S. Preventive Services Task Force guidelines]
  4. history of cervical cancer
  5. have had a hysterectomy.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    eHealth Promotora

    Intervention arm participants will participate in a eHealth promotora group education session to receive a presentation on cervical cancer screening education, view an educational video, and complete baseline and 6-month follow-up surveys.

    Behavioral: eHealth Promotora

  • Active comparator
    eHealth Healthy Nutrition

    Control group participants will participate in an eHealth group education session to receive a presentation on healthy nutrition information, view an educational video, and complete baseline and 6-month surveys.

    Behavioral: eHealth Healthy Nutrition

Interventions

  • BehavioraleHealth Promotora

    Intervention participants attend an eHealth promotora-delivered educational session. Activities include an icebreaker, the completion of a baseline survey, an introduction to cervical cancer using a video and slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore possible barriers and solutions to health care access. Main topics included in the slide presentation are: female anatomy; cervical cancer etiology and disease progression by stage; cancer prevention including diet, exercise, safe sex, cancer screening; human papillomavirus (HPV) vaccine recommendations; Pap test preparations, procedure, screening interval; and information about where to receive a Pap test and seek more information about cervical cancer.

  • BehavioraleHealth Healthy Nutrition

    Control group participants attend an eHealth educational session on healthy nutrition. Activities include an icebreaker, the completion of a baseline survey, an introduction to healthy eating using a video and a slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore benefits and challenges to healthy eating.

06

What researchers measure

Primary outcomes

  1. Cervical cancer screening uptake

    Proportion of participants who complete cervical cancer screening determined by cervical cancer screening measure which asks about the last Pap test completed confirmed by chart review if possible.

    Time frame: 6 months

Secondary outcomes

  1. Cervical cancer screening self-efficacy

    The 10-item cervical cancer screening self-efficacy scale is scored on a 5-item Likert scale ranging from 1 (very unsure) to 5 (very sure) (α = 0.88). Questions include asking participants to rate their confidence in having a discussion with their doctor about the Pap test, scheduling and keeping appointments, getting a Pap test despite being worried about pain, and overcoming embarrassment.

    Time frame: 6 months

  2. Cervical cancer knowledge

    A 15-item cervical cancer knowledge instrument measures educational content of the intervention with 10 True/False questions and 5 multiple choice questions to produce a knowledge score ranging from 0 to 15.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 29 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 29 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 18, 2024
StartActual
Oct 7, 2026was Sep 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Sep 30, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 21, 2026→Oct 7, 2026 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Start date Sep 21, 2026→Oct 7, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06741241
Lead sponsor
Florida A&M University
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Oct 7, 2026
Primary completion
Mar 31, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Professor
Contact
tanise.jackson@famu.edu
8505993214

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion